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Developing robust methodology for the sustainable production of red blood cells in vitro is 25 
essential for providing an alternative source of clini al quality blood, particularly for 26 
individuals with rare blood group phenotypes. Immortalised erythroid progenitor cell lines 27 
are the most promising emergent technology for achieving this goal. We previously created 28 
the erythroid cell line BEL-A from bone marrow CD34+ cells that had improved 29 
differentiation and enucleation potential compared to other lines reported. In this study we 30 
show our immortalisation approach is reproducible for erythroid cells differentiated from 31 
bone marrow, and also from far more accessible periph al and cord blood CD34+ cells, 32 
consistently generating lines with similar improved rythroid performance. Extensive 33 
characterisation of the lines shows them to accurately recapitulate their primary cell 34 
equivalents and provides a molecular signature for immortalisation. In addition, we show 35 
only cells at a specific stage of erythropoiesis, predominantly proerythroblasts, are amenable 36 
to immortalisation. Our methodology provides a step forward in the drive for a sustainable 37 
supply of red cells for clinical use and for the generation of model cellular systems for the 38 
study of erythropoiesis in health and disease, with the added benefit of an indefinite 39 











The restricted availability of blood for transfusion presents a global healthcare problem. As a 42 
result, much work has focused on developing an alterna ive source of clinical-quality red 43 
blood cells, particularly for hard to match patient groups. This includes individuals with rare 44 
blood group phenotypes and chronically transfused patients, such as those with sickle cell 45 
disease, β-thalassemia and some cancers who can develop an alloimmune reaction, 46 
necessitating more extensively blood group matched donors. Cultured red blood cells provide 47 
such an alternative and have additional potential advantages over donor blood, including 48 
reduced risk of disease transmission and the producti n of nascent red cells with improved 49 
survival rates in circulation1.  50 
To date the most efficient stem cells for in vitro culture of erythroid cells are adult peripheral 51 
blood (PB) and umbilical cord blood (CB) haematopoietic stem cells (HSCs). However, 52 
although both types of HSCs can be differentiated to mature erythroid cells1–3, they possess a 53 
limited proliferative capacity, restricting the number of red cells that can be obtained from 54 
each HSC donation.  55 
In recent years immortalised erythroid cell lines have emerged as an alternative approach for 56 
the production of cultured red cells4–8. These lines provide an unlimited supply of early 57 
erythroid cells with only minimal culture required to generate the final product, potentially 58 
enabling a sustainable supply of reticulocytes for clinical use. In addition, such lines serve as 59 
invaluable tools for the study of erythropoiesis in health and disease, providing an indefinite 60 
expansion window for manipulation of molecular targets.  61 
In 2017 we reported the first human immortalised adult erythroid line (BEL-A) from adult 62 
bone marrow (BM) CD34+ cells9. The line was also the first to closely recapitulate normal 63 
adult erythropoiesis. The cells express levels of adult globin equivalent to primary adult 64 











from primary adult erythroid cell cultures. Enucleation capacity of BEL-A was further 66 
improved by subsequent adjustment of the differentiation protocol to give a rate of ∼40%10. 67 
The unlimited proliferative window and ease of molecular manipulation, combined with 68 
unparalleled enucleation capacity, has enabled the application of BEL-A for demonstrating 69 
proof-of-principle production of reticulocytes with increased transfusion compatibility11, 70 
identifying molecular basis of the MAM blood group antigen12 and for the study of surface 71 
protein requirements for Plasmodium falciparum invasion13.  72 
However, isolation of BM CD34+ cells is highly invasive, so the ability to generat  lines from 73 
more accessible PB and CB CD34+ cells is essential for opening up wider applications f the 74 
technology, such as creating lines from individuals with specific and rare blood group 75 
phenotypes, and from patients with erythroid diseases for research purposes.  76 
Despite both PB and BM CD34+ cells originating from the same source, differences have 77 
been detected in their characteristics, including surface marker expression14 and suitability for 78 
allogenic transplant15, which may impact immortalisation potential and phenotype of 79 
resultant lines.  While erythroid cells generated from CB express an increased proportion of 80 
fetal (HbF), which possesses an oxygen dissociation pr file less optimal for adult circulation, 81 
individuals with genetic variants leading to heredity persistence of foetal globin (up to 30% 82 
HbF in adulthood) do not suffer any clinical consequ nces16. Indeed, such observations have 83 
led to the ongoing development of therapeutic  strategies to increase HbF levels in patients 84 
suffering from adult haemoglobinopathies, such as β-thalassemia and sickle cell disease17. 85 
Therefore lines generated from  CB CD34+ cells also have potential for clinical application, 86 
with a particular advantage being their accessibility via human CB banks worldwide, 87 
representing a wider variety of donor ethnicities and genetic backgrounds than from blood 88 











Previous studies describing the generation of immortalised erythroid lines from CB and PB 90 
CD34+ cells have resulted in lines with very poor enucleation capacity (HUDEP-1, HUDEP-91 
2, HUDEP-34; EJ8), that display a globin expression profile differing from the primary cell 92 
source (HUDEP-24) or that require  a stromal cell co-culture system for differentiation which 93 
is not appropriate for scale up or clinical application (iE6), as well as confounding enucleation 94 
efficiency determination due to removal of dead anddying nucleated erythroblasts by stromal 95 
cells. We therefore sought to determine whether our immortalisation approach could generate 96 
lines from CB and PB CD34+ cells with the same improved erythroid phenotype as BEL-A in 97 
our feeder free culture system, and which also closely represent the phenotype of their 98 
parental cell origin. 99 
In addition, all reported erythroid lines to date have been generated by immortalisation of 100 
cells at predominantly the proerythroblast stage of erythroid differentiation. However, 101 
immortalisation of earlier cells when more plastic, or at later stages of erythroid 102 
differentiation, may result in lines with further improved enucleation capacity. 103 
In this study, using our BEL-A immortalisation methodology9 we demonstrate that multiple 104 
cell lines immortalised at different time points in culture from the same donor BM CD34+ 105 
cells all exhibit a predominantly proerythroblast morphology and invariant phenotype 106 
regardless of timing of induced HPV16-E6 and E7 expr ssion. Thus, only pro-erythroblasts 107 
and to a much lesser extent, early basophilic erythroblasts, are amenable to immortalisation. 108 
The data also demonstrate reproducibility of the BEL-A immortalisation approach for BM 109 
CD34+ cells. We next use our methodology to successfully generate lines from the far more 110 
easily accessible CB (BEL-C) and PB (BEL-P) CD34+ cells, with similarly improved 111 
erythroid maturation and enucleation potential as BEL-A and the above BM lines. Extensive 112 
characterisation of the lines, including differentiation, globin expression and proteomics, 113 











has an adult phenotype) demonstrating the reproducibility of our immortalisation approach 115 
across multiple stem cell sources and that immortalisation does not alter the intrinsic and 116 
fundamental erythroid characteristics of the cells. Finally, interrogation of proteomic datasets 117 
across multiple lines provides a signature for HPV16 E6/E7 immortalisation. These findings 118 
pave the way for use of this technology to generate cell lines under GMP as a sustainable 119 
supply of red cells for transfusion and diagnostics, a  well as creation of disease model 120 
systems to investigate underlying molecular defects and to trial novel therapeutics. 121 
 122 
Results 123 
Timing of initiation of HPV16 E6 and E7 expression during line establishment does not 124 
impact characteristics of resultant cell line 125 
The original BEL-A line was generated via transduction of BM CD34+ cells with a Tet-126 
inducible HPV16-E6/E7 expression system4 on day 1 of culture, with cells transferred to 127 
expansion medium containing doxycycline to induce E6/E7 expression on day 59. This 128 
resulted in a cell line comprising predominantly proerythroblasts with a small number of 129 
basophilic erythroblasts9. 130 
We speculated that the timing of initiation of E6 and E7 expression could impact the 131 
properties of the line developed, with the potential o generate cell lines with further 132 
improved terminal differentiation and enucleation potential, for example if cells were 133 
immortalised at a later stage of differentiation. To investigate this possibility, four 134 
immortalised lines were initiated from the same donor BM CD34+ cells. The CD34+ cells 135 
were incubated in the primary medium of our erythroid culture system and transduced with 136 
the Tet-inducible HPV16-E6/E7 construct on day 1 of culture, with transfer to expansion 137 
medium containing doxycycline on day 3, 5, 7 or 9 to induce E6 and E7 expression, referred 138 











composition of the cell population on these days with respect to stage of differentiation is 140 
also shown in Figure 1A. The resulting erythroid lines, td3, td5, td7 and td9, were kept in 141 
expansion culture for over 6 months before being frozen for storage as the lines were 142 
established. The lines showed mean doubling times between 19 and 25 h (Figure 1B) and 143 
consistently high viability (>98% on average) (Figure 1C), with their expansion rate 144 
unchanged over time or after freeze-thawing and further culture (Figure S1A). The oldest 145 
cells cultured to date for td3, td5, td7 and td9 were 202, 203, 184 and 188 days post CD34+ 146 
cell thawing respectively. Surprisingly, despite th differing compositions of erythroid cell 147 
maturation stages present at each of the four time points (Figure 1A), all four lines exhibited 148 
a predominantly proerythroblast morphology, with small numbers of early basophilic 149 
erythroblasts (Figure 1D; td3 86±4%, td5 84±5%, td7 83±6%, td9 88±7% proerythroblasts). 150 
Hence, although for example at day 9 the predominant cell types present were basophilic 151 
(51%) and polychromatic erythroblasts (22%), with only 23% proerythroblasts, it was still 152 
predominantly proerythroblasts that became immortalised. At day 3 there were no 153 
proerythroblasts detected, the majority of cells being early progenitors with a small number 154 
(24%) of pre-proerythroblasts. However, the resultant cell line (td3) again comprised 155 
predominantly proerythroblasts, E6 and E7 although expressed earlier clearly not taking 156 
effect until the cells had differentiated to this stage. It therefore appears that only 157 
proerythroblasts and early basophilic erythroblasts re amenable to immortalisation, at least 158 
with this technique.  159 
To further investigate the maturation stage of the immortalised lines, flow cytometry was 160 
performed for cell surface maker proteins known either to increase (glycophorin A (GPA), 161 
band 3) or to decrease (CD36, α4-integrin, CD71) during erythroid differentiation20. 162 
Consistent with the observed morphology, all four lines showed a similar surface marker 163 










Next we compared the behaviour of the four lines during differentiation by transferring 165 
expanding cells to our erythroid culture system11. Although td3 and td5 trended towards a ∼2-166 
fold greater expansion rate during differentiation, ly td3 vs td9 at day 8 and day 14 (P= 167 
0.03 and P= 0.005 respectively) reached significance (Figure 2Ai). There were no significant 168 
differences in viability detected (Figure 2Aii), with a decline in viability in all lines from day 169 
8, as found with the original BEL-A line whereby cells that fail to enucleate enter apoptosis10. 170 
Morphological analysis showed the differentiation potential of all four lines was also similar 171 
(Figure 2 B and C), with only slight differences in differentiation rates at early time points. 172 
However, such discrete, defined stages by morphological analysis are selected within a 173 
continuum of differentiation, with further analysis by flow cytometry revealing no significant 174 
difference in levels of GPA, band 3, CD36 and α4-integrin (Figure 2D) at any time point, 175 
indicating high level of similarity between the lines. There was also no significant difference 176 
in enucleation rates (Figure 2Aiii). The differentiation potential and rate for cells from the 177 
same line at different time points post immortalisation were consistent (Figure 2), with cells 178 
at day 200, 199, 182 and 186 for td3, td5, td7 and td9 respectively the oldest differentiated to 179 
date. Western blot analysis of differentiated cells confirmed an adult globin expression 180 
profile for all four lines equivalent to that seen for BEL-A and for primary adult erythroid 181 
cells, with high levels of β-globin and negligible γ-globin (Figure S2).  182 
Overall, these results demonstrate that immortalising populations of erythroid cells by 183 
transduction of HPV16 E6/E7 at progressively later stages of differentiation culture does not 184 
result in a line comprising correspondingly later stage cells. Instead only proerythroblasts, 185 
and to a lesser extent early basophilic erythroblasts, re amenable to immortalisation, with the 186 
four lines generated exhibiting similar characterisics and behaviour. The data also 187 












The BEL-A immortalisation protocol is reproducible for generating lines from more 190 
accessible cord and adult peripheral blood stem cells  191 
Next we wanted to determine whether we could generate lines with similar recapitulation of 192 
erythropoiesis from the more accessible CB and PB CD34+ cells, and that are also 193 
representative of their parental stem cell type (that is with a fetal and adult phenotype 194 
respectively). 195 
The data above reveal no difference in the phenotype of lines created at different time points 196 
in culture, albeit with a possible expansion advantage of lines made at earlier time points. 197 
Moreover, for generation of the original BEL-A cell line HPV16-E6 and E7 expression was 198 
induced at an early time point (day 5)9. Therefore, an equivalent protocol was used to attemp  199 
generation of immortalised lines from CB and PB stem cells. 200 
Lines from both CB (BEL-C; Bristol Erythroid Line Cord,) and PB (BEL-P; Bristol 201 
Erythroid Line Peripheral Blood) CD34+ cells were successfully established, with continued 202 
expansion in culture for over 6 months before being frozen for storage. Expansion rates for 203 
the lines did not change over time or following freez -thawing and further culture (Figure 204 
S1B). The oldest cells cultured to date were 183 and 181 days post CD34+ cell thawing for 205 
BEL-C and BEL-P respectively. BEL-C and BEL-P showed a predominantly proerythroblast 206 
morphology similar to BEL-A and additional cell lines above (Figure 3A; BEL-C 80±4%, 207 
BEL-P 77±5% proerythroblasts), exhibited mean doubling times of 26 h (Figure 3B) and 208 
maintained high viability during expansion (average >97%) (Figure 3C). There was no 209 
change in phenotype or morphology of the cells over time and cells re-established efficiently 210 
in culture following freeze thawing. When induced to differentiate, both lines displayed 211 
broadly similar expansion, viability and enucleation profiles, with maximum enucleation 212 
rates of ∼26% on day 14 (Figure 3D). Leaving the cells in culture for longer did not result in 213 










enucleate entering apoptosis, as seen with BEL-A10. The differentiation potential and rate of 215 
cells from the same line at different time points post immortalisation were consistent (Figure 216 
3), with cells for BEL-C and BEL-P at day 128 and 140 respectively the oldest differentiated 217 
to date.  218 
 219 
Molecular Karyotyping of immortalised cell lines  220 
As potential model systems, it is important to determine the extent of karyotype abnormalities 221 
in immortalised cell lines, especially when considering genome editing applications. To 222 
assess this, molecular karyotyping of established BEL-C and BEL-P cells, alongside samples 223 
of the td3, td5, td7 and td9 lines (all >150 days of c ntinuous culture) was performed by 224 
single nucleotide polymorphism array (SNP-array) analysis. As has been previously observed 225 
for both BEL-A10 and HUDEP-221,22 which were immortalised using the same HPV-16 E6 226 
and E7 expression system, all lines showed a number of whole or partial trisomies, with some 227 
lines exhibiting whole or partial chromosome loss (detailed in Table S1). The average 228 
chromosome numbers in the lines ranged from 46 to 51 based on a threshold of 30% 229 
abnormality frequency determined by LogR ratio (BEL-C, 46 XY; BEL-P 51 XX; td3, 50 230 
XX; td5, 50 XX; td7, 49 XX; td9, 48 XX). The most prevalent trisomies detected at the 30% 231 
threshold were of chromosome 8 (all lines) and 19 (BEL-P, td3, td5 and td9) (Figure S3).  232 
 233 
The BEL-C and BEL-P lines recapitulate phenotype of respective primary stem cell 234 
sources 235 
As well as demonstrating successful immortalisation of CB- and PB-derived erythroid cells 236 
using the BEL-A protocol, along with efficient erythroid differentiation, we wanted to 237 
determine whether the lines model their primary stem cell source in terms of erythroid 238 











rates and profiles, cultures were initiated from both expanding BEL-C and BEL-P cells and 240 
from CB and PB CD34+ cells in parallel.  Cell samples were taken at regular intervals for 241 
analysis, which for the primary cell cultures was from day 5 as this is the time point when 242 
HPV16 E6 and E7 expression was induced in the lines (i.e. is equivalent to the 243 
undifferentiated BEL-C and BEL-P cells). 244 
Differentiation potential of BEL-C and BEL-P compared with primary CB and PB 245 
erythroid cells 246 
Morphological analysis shows that both BEL-C and BEL-P undergo erythroid differentiation 247 
in line with that of the respective CB and PB primary cell cultures, albeit with less 248 
heterogeneity in erythroid cell types during mid-differentiation (Figure 4 A and B). BEL-C 249 
differentiation cultures show an increased proportion of early stage erythroid cells during 250 
mid-differentiation compared to BEL-P, with significantly more basophilic erythroblasts at 251 
day 6 and 8 (P=0.001 and P=0.006 respectively). This is consistent with the profile for CB 252 
and PB primary cell cultures where a similar prevalnce of early stage cells is seen in CB 253 
compared to PB cultures, with a significant differenc  in the proportion of basophilic 254 
erythroblasts at day 13 (P=0.02).  255 
For more detailed analysis of differentiation, the inverse expression of GPA vs CD36 and 256 
band 3 vs α4-integrin was measured by flow cytometry (Figure 4C). BEL-C and BEL-P 257 
exhibited a similar surface marker profile throughout differentiation to their primary cell 258 
counterparts, albeit with reduced heterogeneity and  lack of cells with a more immature 259 
immunophenotype at the early time points (most clearly seen by the CD36 and GPA double 260 
negative population present at day 5 and day 7 in the CB and PB cultures). In addition, a 261 
greater prevalence of cells with a more immature cell surface marker expression during 262 
differentiation is apparent in the BEL-C and CB cultures compared to the BEL-P and PB 263 











band 3 median fluorescence intensity (Figure S4), in line with the earlier erythroid cell types 265 
observed from morphological analysis during mid-differentiation (Figure 4A). Interestingly, 266 
these data also show that while there is heterogenous surface marker expression in the CB 267 
and PB cultures at the time point of immortalisation (i.e. day 5, Figure 4C) only a 268 
subpopulation of these cells are immortalised, represented by the surface marker profile of 269 
the undifferentiated cell lines (day 0, Figure 4C), providing further evidence for the 270 
preferential immortalisation of a distinct proerythroblast/early basophilic erythroblast 271 
population.  272 
Comparison of globin expression profiles of BEL-C and BEL-P cell lines with CB and PB 273 
primary cells  274 
To investigate whether the globin expression profiles of the BEL-C and BEL-P lines reflect 275 
their stem cell origin, samples of mature erythroid cells were collected from late-stage 276 
cultures of the lines and primary cells for reverse phase high performance liquid 277 
chromatography (RP-HPLC) and western blot analysis. As can be seen in Figure 5A, B and 278 
C, erythroid cells differentiated from CB CD34+ cells express predominantly γ- but with 279 
some β-globin, reflecting heterogeneity in the population due to the developmental globin 280 
switch (from γ- to β-globin) which commences just prior to birth and continues to ∼6 months 281 
of age, and presence of CD34+ cells originating from both fetal liver and bone marrow23. In 282 
contrast, erythroid cells differentiated from PB CD34+ cells express β-globin with very low 283 
levels of γ-globin (Figure 5A, B and C). Accordingly, the BEL-P line expresses almost 284 
exclusively β-globin, the lower level of γ-globin compared to the PB-derived erythroid cells 285 
(more clearly seen by western blot; Figure 5C) likely due to variation between the donors. 286 
Similarly, the BEL-C line expresses predominantly γ-globin with very low levels of β-globin 287 
(Figure 5A, B and C), indicating a fetal phenotype. Differences in the γ-globin:β-globin ratio 288 











circumstantial immortalisation of cells of fetal liver origin expressing predominantly γ-globin 290 
in the original CB sample. Hence, the two lines represent the desired fetal and adult 291 
phenotypes in terms of globin expression profile. 292 
In addition, we looked at the expression of key erythroid transcription factors, in particular 293 
those involved in the regulation of globin expression, at early and mid-stage differentiation 294 
by western blot along with densitometry analysis, selecting time points to match cells at as 295 
similar stages of maturation as possible. A representative western blot is shown in Figure S5. 296 
There was no statistically significant difference in the level of GATA1 and KLF1 protein in 297 
BEL-C and BEL-P compared to CB- and PB-derived erythroid cells respectively (Figure 5C), 298 
or in the level of BCL11A between BEL-P and PB-deriv d erythroid cells. In contrast, the 299 
level of BCL11A was significantly lower in BEL-C compared to CB-derived cells (P=0.04; 300 
Figure 5C). As BCL11A inhibits γ-globin expression24 this is in line with the predominance 301 
of γ-globin expression and much lower level of β-globin in BEL-C. Such a correlation 302 
between BCL11A and γ-globin is supported by erythroid cells differentiated from CB CD34+ 303 
cells whereby those with lower levels of γ-globin have higher levels of BCL11A (Figure S6), 304 
also demonstrating variation in levels between donor samples. 305 
Comparative proteomic analysis of BEL-C and BEL-P cell lines with CB and PB primary 306 
erythroid cells 307 
Finally, for a comprehensive comparative analysis of expanding BEL-C and BEL-P with 308 
their primary erythroid cell equivalents, we performed Tandem Mass Tag (TMT) LC-MS/MS 309 
quantitative proteomics.  310 
To obtain CB and PB erythroid cells stage-matched to expanding BEL-C and BEL-P, CD34+ 311 
cells were initially cultured in our primary erythroid medium to induce differentiation, 312 
followed by a further 2 days in expansion medium (Figure S7); the period in expansion 313 











the culture medium the cells were exposed to. Cells were obtained from 3 independent 315 
cultures of BEL-C and BEL-P cell lines and 2 independ nt cultures of pooled CB and pooled 316 
PB CD34+ samples; the pooled samples to quench differences in protein levels due to 317 
variation between individuals rather than between lines and primary cells. Data for BEL-P 318 
was compared to that for PB and data for BEL-C compared to that for CB. 319 
LC-MS/MS of peptides derived from whole cell lysates gave quantitative data for 8,367 320 
proteins for BEL-C vs CB comparison and 8,368 proteins for BEL-P vs PB comparison. 321 
Protein abundances were normalised to total protein abundance, ensuring that any differences 322 
in individual protein abundance detected was not due to differences in the total protein input 323 
between samples. Heat maps of these data showed a very similar overall pattern of 324 
normalised protein abundances between the BEL-C and CB samples (Figure 6A, left panel) 325 
and the BEL-P and PB samples (Figure 6A, right panel). 326 
To display the frequency and magnitude of differences in the proteome of each cell line and 327 
primary erythroid cell equivalent, volcano plots were generated depicting -log10 p-value and 328 
log2 fold change for each protein hit (Figure 6B). When a false discovery rate (FDR) 329 
threshold for significance was applied, only 2.06% of proteins were significantly ≥2-fold 330 
lower and 1.65% significantly ≥2-fold higher in abundance in BEL-C compared to CB 331 
(Figure 6B, left panel), and only 1.96% of proteins were significantly ≥2-fold lower and 332 
1.40% significantly ≥2-fold higher in abundance in BEL-P compared to PB (Figure 6B, right 333 
panel).  334 
To further determine if BEL-C and BEL-P model their primary stem cell source, i.e. a fetal 335 
phenotype for BEL-C and adult phenotype for BEL-P, we interrogated the datasets for 336 
proteins known to be differentially expressed betwen fetal and adult erythroid cells. 337 
Although at an early time point for complete globin expression, the profile of β- and γ-globin 338 











B). In addition, the levels of embryonic ε- and ζ-globins were higher in BEL-C than in CB-340 
derived erythroid cells (Figure 6C, upper panel), again indicating that this line has a more 341 
fetal globin phenotype. Expression of these embryonic globin subunits is also repressed by 342 
BCL11A24–26, so these data reflect the lower BCL11A levels observed in BEL-C. As 343 
expected ε- and ζ-globin were at a very low level in BEL-P and PB-deriv d erythroid cells 344 
(Figure 6C, upper panel). Analysis of other proteins k own to be at a higher level in fetal 345 
compared to adult erythroid cells (IGF2BP1 & IGF2BP327, LIN28B28), or at a lower level 346 
(BCL11A24 and LRF29) further confirmed the fetal erythroid phenotype of BEL-C and adult 347 
phenotype of BEL-P (Figure 6C; lower panel); IGF2BP1, IGF2BP3 and LIN28B were 348 
significantly higher in BEL-C than in BEL-P, and BCL11A and LRF were significantly 349 
higher in BEL-P than BEL-C. Interestingly, IGF2BP1, IGF2BP3 and LIN28B were 350 
significantly lower in CB-derived erythroid cells compared to BEL-C, and BCL11A and LRF 351 
significantly higher, supporting the globin profile and existence of a heterogenous population 352 
of both fetal and adult-like cells in CB samples due to timing of the developmental globin 353 
switch, as mentioned above. This mixed population also explains why BCL11A and LRF, 354 
typically increased in adult erythroid cells, are significantly higher in BEL-P compared to 355 
BEL-C, but not compared to CB (Figure 6C; lower panel). The relative levels of IGF1BP1, 356 
IGF2BP3 and LIN28B were confirmed by western blot (Figure S8).  357 
Finally, to determine whether the difference in proteome between the lines and respective 358 
primary cells is attributable to HPV16 E6 and E7 expr ssion, and thus revealing the 359 
mechanism for immortalisation, we compared the ≥2-fold differentially expressed proteins 360 
across proteomic datasets for four lines. 43% of the proteins were common between BEL-C 361 
and BEL-P and of these 56% were also ≥2-fold different in BEL-A compared to primary 362 
cells. 86% of the changes common between these threlines were similarly ≥2-fold different 363 










datasets unpublished). This increasing commonality demonstrates the need for analysis across 365 
several cell lines to generate a list of protein changes that can be confidently attributed to 366 
HPV16 E6/E7 immortalisation rather than other factors, for example donor variation in the 367 
cells used for line generation compared to the primary cell cultures. Proteins that differed in 368 
abundance by ≥2-fold between the cell lines and respective primary cells across all 4 datasets 369 
are shown in tables S2 and S3. Analysis of these diff rentially expressed proteins for over 370 
represented biological pathways using the Reactome pathway knowledgebase30 revealed 371 
multiple pathways related to  cell cycle regulation, including  evasion of cellular senescence, 372 
G1 phase and G1/S phase transition (Table 1), highlighting their association with HPV16 373 
E6/E7. When considering the proteins featured within e top 20 pathways identified, four 374 
cell cycle proteins appeared most frequently: CDK4 (18/20), CDK6 (16/20), p16INK4A (16/20) 375 
and Rb (9/20). On average across all four lines, CDK4 was increased 3-fold, p16INK4A was 376 
increased 6-fold, CDK6 was decreased 8-fold and Rb decreased 3-fold compared to primary 377 
cells, providing a molecular signature of these altred cell cycle proteins (Figure 7).  378 
Overall, the data show that the BEL-C and BEL-P cell lines provide representative cellular 379 
systems of fetal and adult erythroid cells respectiv ly in terms of their proteome, globin 380 
expression and differentiation profile.  Moreover, the data provides a molecular signature for 381 
immortalisation.   382 
 383 
Discussion 384 
In this study we show that our immortalisation approach used to create BEL-A9 is 385 
reproducible for erythroid cells differentiated from BM and importantly also from CB and PB 386 
CD34+ cells, consistently generating lines with similar mproved erythroid performance.  387 
We also show that, at least with our approach, only erythroid cells at a discrete stage of 388 










extent early basophilic erythroblasts. Efficiency of proerythroblasts and failure of later stage 390 
erythroid cells to immortalise may be attributable to a lower proportion of HPV16-E6 and E7 391 
target proteins as differentiation proceeds, reducing the efficiency of E6 and E7 activity, as 392 
the total protein content of erythroblasts decreases during differentiation31. Failure of earlier 393 
cell stages to immortalise in these cultures, particularly HSCs, may be for this same reason, 394 
HSCs having lower levels of protein synthesis than lineage-restricted haematopoietic cell 395 
types32. Alternatively, this may relate to the observed instability of these progenitors that do 396 
not exist as stable states but as constantly changing entities33,34, severely reducing the window 397 
to immortalise specific erythroid lineage progenitors. While we cannot exclude the possibility 398 
that some later stage erythroid cells do get immortalised but are outcompeted during line 399 
establishment due to slower division rates, morphological analysis of our lines during this 400 
period showed very few such cells, suggesting this is unlikely.  401 
The lines reported here all have improved enucleation potential/rates compared to that of 402 
other erythroid lines in the literature5 ven those generated from the same stem cell sources 403 
and using the identical construct (HUDEP lines4, BMDEP-1 lines7 and EJ line8). However, as 404 
previously discussed10 the measure of reticulocyte yield, rather than rate as routinely used, 405 
provides a more transparent and accurate assessment of the reticulocyte productivity of a line, 406 
as it accounts for expansion potential and cell death (which for many lines can be substantial) 407 
during differentiation; as more nucleated cells die th  proportion of reticulocytes (and thus 408 
the apparent enucleation rate) increases, compounded by the use of co-culture with stromal 409 
cells that remove dead or dying erythroblasts. For HUDEP-2, generated from CB CD34+ 410 
cells, we have previously calculated the yield under i ntical culture conditions10, which is 411 
∼50% lower than for BEL-C. Reticulocyte yield of the EJ line, generated from PB CD34+ 412 
cells, is 10 times lower than for BEL-P8. Viability data was not available for the BMDEP-1 413 











reported as very low4. Nevertheless, the enucleation rate of BEL-C and BEL-P is lower than 415 
for our original line, BEL-A (~26% vs ~40%). This could be due to variation in how the 416 
immortalisation mechanism effects cells during creation of the different lines, or due to donor 417 
variation. Notwithstanding, the enucleation rate of BEL-A is lower than that of non-418 
immortalised erythroid cells differentiated from adult CD34+ cells1,3, the basis for which is 419 
presently under investigation and may also inform variation between lines.  420 
Extensive characterisation and analyses of BEL-C and BEL-P show them to accurately 421 
recapitulate their primary cell equivalents in terms of differentiation profile, globin 422 
expression and proteome, with ≤2% of proteins significantly upregulated or downregulated. 423 
Moreover, from analysis of consistent differences in the proteome identified across BEL-C, 424 
BEL-P, BEL-A and an additional erythroid line made from BM CD34+ cells, we reveal a 425 
molecular signature of differences in key cell cycle proteins CDK4, CDK6, P16INK4A and Rb 426 
as a result of immortalisation by HPV16 E6 and E7. 427 
Rb is the primary target of E735 and can induce its degradation via the ubiquitin-proteasome 428 
pathway36, in keeping with the lower levels observed in the immortalised lines.  HPV16 E7 429 
has also been shown to promote p16INK4A expression in cervical carcinoma lines, with 430 
p16INK4A required for cell survival37. In addition, as p53 is necessary for p16INK4A 431 
repression38, it is likely that the decreased level of p53 in the immortalised lines (due to 432 
degradation of p53 by E639,40) contributes to increased p16INK4A  expression. Both CDK4 and 433 
CDK6 are activated by D-type cyclins to drive cell cycle progression from G1 to S phase41. 434 
In line with the increased levels seen in the immortalised lines, CDK4 is known to be 435 
increased in many tumour types42–45. In contrast to the generally increased expression pattern 436 
seen in cancer46, CDK6 is reduced in the immortalised lines, potentially compensating for 437 
increased CDK4 levels. As CDK6 has been previously reported to counteract the p53-438 










the lines is not required as p53 is already being de raded by E6. While these changes are 440 
associated with continual self-renewal, they do not alter the fundamental erythroid biology of 441 
the lines or impair their ability to differentiate upon removal of doxycycline and therefore 442 
loss of E6 and E7.  443 
In addition to providing novel data on proteome changes associated with HPV16 E6/E7 and 444 
thus mechanism of immortalisation, the molecular signature of altered cell cycle proteins 445 
identified offers a valuable resource for identifying alternative methods of immortalisation of 446 
erythroid progenitors that do not rely on viral oncproteins.  One possible strategy is the 447 
overexpression of CDK4, which has previously been utilised to generate keratinocyte and 448 
myoblast immortalised cell lines in combination with hTERT expression48–51. Such, more 449 
targeted approaches may yield erythroid lines with further improved characteristics by only 450 
generating the minimal number of alterations necessary for immortalisation, avoiding the 451 
potentially broader impact of viral oncogene expression.  452 
Overall, these data expand the application of our immortalisation methodology and provide a 453 
significant step forward in the drive for a sustainable supply of red cells with specific blood 454 
group phenotypes for therapeutics and diagnostics using PB, CB or BM CD34+ cells. In 455 
addition, the methodology can be applied to create lin s with disease phenotypes for 456 
investigating underlying molecular defects and as drug screening platforms52. In particular, 457 
BEL-C and BEL-P provide valuable research tools with which to evaluate novel approaches 458 
for conversion of fetal to adult and adult to fetal globins in treatment of globin gene 459 















Cell lines were generated as previously described unless otherwise stated9. Briefly, 5×105 - 465 
1×106  cryopreserved BM, CB or PB CD34+ cells (Stemcell Technologies), were recovered in 466 
erythroid differentiation medium (Iscove’s medium with stable glutamine [Merck] containing 467 
3% (v/v) AB serum  [Merck], 2% (v/v) fetal bovine serum [Hyclone], 10 µg.ml-1 Insulin 468 
[Merck], Heparin 3U.ml-1 [Merck], 200 µg.ml-1 holo-transferrin [Sanquin, NED] and 3U.ml-1 469 
EPO [Roche]) supplemented with 1 ng.ml-1 IL‐3 and 10 ng.ml-1 SCF (both R&D Systems) 470 
(primary medium) for 24 h, before being transduced with the lentiviral vector CSIV-TRE-471 
HPV16-E6/E7-UbC-KT and maintained in primary medium for a further 4 days (or until day 472 
3, 5, 7 or 9 in the case of the td cell lines). To induce expression of HPV16-E6 and E7, cells 473 
were transferred to expansion medium (StemSpan™ SFEM [Stemcell Technologies] 474 
containing 50 ng.ml-1 SCF, 3 U.ml-1 EPO, 1 µM dexamethasone and 1 µg.ml-1 doxycycline) 475 
and maintained in this medium for at least 6 months before cryopreservation for long-term 476 
storage.  477 
Differentiation of cell lines was performed as previously described11. In brief, expanding cells 478 
were transferred to primary medium supplemented with 1 µg.ml-1 doxycycline for 4 days, and 479 
for a further 4 days without doxycycline. Cells were then transferred to erythroid 480 
differentiation medium supplemented with holo-transferrin to a final concentration of 500 481 
µg.ml-1.  482 
 483 
Erythroid differentiation culture of BM, CB and PB derived CD34+ cells  484 
Erythroid differentiation of CD34+ cells was performed as previously described3. In brief, 485 
CD34+ cells were seeded in primary medium at a density of 1-2×105 cells.ml-1. On day 7, 486 
cells were transferred to differentiation medium supplemented with 10 ng.ml-1 SCF, and from 487 
days 11 to 21 cells to differentiation medium with additional holo-transferrin to a final 488 











Flow cytometry 490 
Aliquots of 2×105 cells were incubated with primary antibodies in PBS containing 1% (w/v) 491 
BSA (Park Scientific Ltd) and 2 mg.ml-1 glucose (PBS-AG), followed by secondary 492 
antibodies (along with conjugate antibodies when appro riate). Cells were analysed on a BD 493 
LSR Fortessa flow cytometer. Propidium iodide was used to exclude non-viable cells from 494 
analyses. From mid-differentiation onwards (day 6 for cell lines and day 9 for primary 495 
erythroid cultures) cells were incubated with 5 µg.ml -1 Hoechst 33342 nucleic acid stain 496 
(Merck) to distinguish the erythroblast and reticulocyte populations. Data were analysed 497 
using FlowJo v10.6.1 (FlowJo LLC).  498 
TMT labelling, mass spectrometry and data analysis  499 
TMT LC-MS/MS comparative proteomic experiments were p rformed as previously 500 
described11 with the following adaptions. Aliquots of 100 µg of protein from whole cell 501 
lysates were digested with trypsin (2.5 µg trypsin, 37 °C overnight) and labelled with 502 
Tandem Mass Tag (TMT) eleven-Plex reagents according to the manufacturer’s protocol 503 
(Thermo Fisher Scientific) before labelled samples w re pooled.  504 
Data analyses were performed on log2 normalised abundances using an un-paired, 2-tailed, 505 
heteroscedastic Student’s t-test in Microsoft Excel. A 5% false discovery rate (FDR) 506 
threshold for each comparison was calculated using R Studio. For data visualisation, 507 
heatmaps with Ward’s cluster analysis and volcano plots were generated using R Studio.  508 
Statistical analysis  509 
For statistical analysis of >2 groups, following Shapiro-Wilk normality testing Welch’s 510 
ANOVA with Dunnet’s multiple comparison testing was performed. For analysis of 2 groups, 511 
a Welch’s t-test was performed. In both cases, statistical tests were performed in GraphPad 512 
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Figure Legends 722 
 723 
Figure 1. Only early erythroid cells, predominantly proerythroblasts, display efficient 724 
immortalisation potential. (A) Schematic of the td3, td5, td7 and td9 cell line i itiation 725 
protocol. Vertical bars depict morphology data obtained from cytospins of BM CD34+ cell 726 
erythroid culture at day 3, 5, 7 and 9 of differentiation. Pre-proE, pre-proerythroblast; ProE, 727 
proerythroblast; BasoE, basophilic erythroblast; PolyE, polychromatic erythroblast; OrthoE, 728 
orthochromatic erythroblast; Retic, reticulocyte. (B-E) Characterisation of the td3, td5, td7 729 
and td9 cell lines during the undifferentiated stage. (B) Doubling time and (C) percentage 730 
viability determined by trypan blue exclusion assay of established cell lines from day 152-731 
198 of expansion culture. Data are shown as mean ± standard deviation (SD). (D) 732 
Representative images from cytospins of cell line expansion cultures. Scale bars 20 µm. (E) 733 
Expression of GPA, band 3. CD36, α4-integrin and CD71 in the undifferentiated cell lines as 734 
determined by flow cytometry (n=3) with median fluorescence intensity (MFI) frequency 735 
distributions normalised to mode. Histograms are representative of three independent 736 
experiments.  737 
 738 
Figure 2. Characterisation of td3, td5, td7 and td9 cell lines during differentiation. 739 
Expanding cells (day 0) were transferred to erythroid differentiation medium and samples 740 
taken at time points throughout differentiation. (A) (i) Cumulative fold expansion, (ii) 741 
percentage viability and (iii) percentage enucleation of the differentiating td3, td5, td7 and 742 










lines (ProE, proerythroblast; BasoE, basophilic erythroblast; PolyE, polychromatic 744 
erythroblast; OrthoE, orthochromatic erythroblast; Retic, reticulocyte) and (C) representative 745 
images from cytospins of these cultures at day 0, 4, 8 and 12 of differentiation. Scale bars 20 746 
µm. Arrow heads indicate the following cell types: white, ProE; blue, BasoE; orange, PolyE; 747 
black, OrthoE; red, Retic. (D) Median fluorescence int nsity (MFI) of GPA, band 3. CD36 748 
and α4-integrin in the differentiating cell lines as determined by flow cytometry. 749 
Differentiation cultures were initiated between 154 and 200 days of continual expansion since 750 
the source CD34+ cells were thawed.  Data are shown as mean ± SD, n=3. 751 
 752 
Figure 3. Characterisation of erythroid cell lines derived from PB and CB CD34+ cells. 753 
(A-C) Characterisation of the CB-derived (BEL-C) and PB-derived (BEL-P) cell lines during 754 
the undifferentiated stage. (A) Representative images from cytospins of BEL-C and BEL-P 755 
expansion cultures. Scale bars 20 µm.  (B) Doubling t me and (C) percentage viability 756 
determined by trypan blue exclusion assay of establi hed cell lines from day 92-146 of 757 
expansion culture. (D) (i) Cumulative fold expansion, (ii) percentage viability and (iii) 758 
percentage enucleation of the differentiating BEL-C and BEL-P cell lines. (n=3). 759 
Differentiation cultures were initiated between 100 and 140 days of continual expansion since 760 
the source CD34+ cells were thawed. Data are shown as mean ± SD. 761 
 762 
Figure 4.  Comparison of differentiating BEL-C and BEL-P cell lines with erythroid cell 763 
differentiation from respective cord blood and adult peripheral blood CD34+ cells. (A) 764 
Percentage of erythroid cell types present during differentiation of BEL-C, CB, BEL-P and 765 
PB cells during erythroid differentiation (Pre-proE, pre-proerythroblast; ProE, 766 
proerythroblast; BasoE, basophilic erythroblast; PolyE, polychromatic erythroblast; OrthoE, 767 











cytospins of these cultures. Scale bars 20 µm. Arrow heads indicate the following cell types: 769 
green, Pre-proE; white, ProE; blue, BasoE; orange, PolyE; black, OrthoE; red, Retic. Data are 770 
shown as mean ± SD (n=3). (C) Flow cytometry analysis of band 3 vs α4-integrin and GPA 771 
vs CD36 cell surface expression of BEL-C, BEL-PO, CB and PB cells during erythroid 772 
differentiation. Plots are representative of three independent cultures.  773 
 774 
Figure 5. Globin and erythroid transcription factor expression in BEL-C, BEL-P, CB 775 
and PB cells. 776 
(A-B) Reversed-phase high-performance liquid chromat graphy (RP-HPLC) of BEL-C and 777 
BEL-P cells at day 10 of differentiation, and CB and PB cells at day 17 of differentiation. (A) 778 
Representative RP-HPLC trace. The injection peak is identified along with peaks for β-globin 779 
(β), Gγ-globin (Gγ), α-globin (α) and Aγ-globin (Aγ); δ-globin expression is below the 780 
detection limit. (B) Quantification of RP-HPLC data showing percentage of α-, β- and γ-781 
globin (Gγ + Aγ) subunits detected. Data are shown as mean ± SD (n=3). (C) Western blots of 782 
lysates obtained from BEL-C and BEL-P erythroid cells at day 10 of differentiation, and CB 783 
and  PB erythroid cells at day 17 of differentiation ncubated with antibodies to α-, β- and γ-784 
globin. α-globin was used as a protein loading control. (D) Densitometry analysis from 785 
western blots of lysates obtained from early and mi-differentiation cultures (day 0/4 for 786 
BEL-C and BEL-P and day 5/9 for CB and PB for early/middifferentiation respectively) 787 
incubated with antibodies to BCL11A, GATA1 and KLF1 normalised to β-actin. Data are 788 
shown as mean ± SD (n=2). *P < .05 Welch’s t-test (all other relevant cell line vs primary 789 
cell comparisons are statistically non-significant).  790 
 791 
Figure 6.  TMT LC-MS/MS comparative proteomic analysis of undifferentiated BEL-C 792 










data from BEL-C and CB samples (left panel) and BEL-P and PB samples (right panel) 794 
presented as log2 normalised abundance values. Yellow indicates high protein expression 795 
level; purple indicates low protein expression leve. Lane labels indicate samples collected 796 
from independent cultures. (B) Volcano plots of the proteomic data of all culture repeats from 797 
BEL-C and CB samples (left panel) and BEL-P and PB samples (right panel) depicting-log10 798 
p-value and log2 fold change for each protein hit which had data avil ble from all repeats. 799 
P<0.05 and Q<0.05 (FDR) thresholds are indicated by red dashed lin s. Percentages indicate 800 
the proportion of protein hits that showed a >2-fold difference in abundance between the cell 801 
line and the primary cells and also passed the FDR threshold. (C) Levels of globins and other 802 
key fetal/adult proteins in undifferentiated BEL-C and BEL-P cells with stage-matched 803 
equivalent primary cells.  Data from TMT LC-MS/MS comparative proteomic analysis are 804 
abundance values normalised to total protein shown as mean ± SD (n=2 for CB and PB and 805 
n=3 for BEL-C and BEL-P). ▲Globin abundances are further normalised to α-globin 806 
abundance. *P < .05, **P < .01, ***P < .001, ****P < .0001. P-values represent results from 807 
Welch’s ANOVA performed on log2 normalised data.  808 
 809 
Figure 7. Signature cell cycle protein alterations in immortalised erythroid cell lines 810 
compared to primary cells. Average fold differences in key cell cycle proteins obtained 811 
from proteomic data of four immortalised erythroid cell lines (BEL-C, BEL-P, BEL-A and 812 











Table 1. Altered biological pathways in immortalised erythroid cell lines compared to 814 
equivalent primary cells. Pathways generated by input of proteins where abundance differed 815 
by ≥2-fold in all of the BEL-C, BEL-P, BEL-A and BM cell line datasets into the Reactome 816 


















Top 20 altered biological pathways in immortalised erythroid cell lines compared to primary cells 
Oncogene Induced Senescence 
Diseases of cellular response to stress 
Diseases of Cellular Senescence 
Cellular Senescence 
Evasion of Oxidative Stress Induced Senescence Due to p16INK4A Defects 
Evasion of Oncogene Induced Senescence Due to p16INK4A Defects 
Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 
Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 
Oxidative Stress Induced Senescence 
Cyclin D associated events in G1 
G1 Phase 
Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 
Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 
Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects 
Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) 
Formation of Senescence-Associated Heterochromatin Foci (SAHF) 
Apoptotic execution phase 
Cellular responses to external stimuli 
Mitotic G1 phase and G1/S transition 









Here Daniels et al. demonstrate reproducible immortalisation of erythroid cells derived from bone 
marrow, peripheral and cord blood CD34
+
 cells and reveal a molecular signature of immortalisation. 
This methodology provides a step towards the sustainable production of red cells for clinical use and 
for the generation of cellular model systems. 
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